Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 3, 2003, Pages 235-241

  Scherstén, Fredrik ^a,d   Wahlund, Göran ^b   Björnheden, Tom ^c   Carlsson, Stefan ^b   Mattsson, Christer ^b   Grip, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d Department of Cardiology/PCI ^*  (Sweden)

Author keywords

Angioplasty; Anticoagulants; Fibrin; Heparin; Inhibitor; Platelets; Thrombin; Vascular injury

Indexed keywords

HEPARIN; MELAGATRAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; CELL LABELING; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; FEMALE; FIBRIN DEPOSITION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RIGHT CORONARY ARTERY; THROMBOCYTE AGGREGATION; THROMBUS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; AZETIDINES; BENZYLAMINES; BLOOD PLATELETS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRIN; FIBRINOLYTIC AGENTS; GLYCINE; MALE; MODELS, ANIMAL; PLATELET ADHESIVENESS; RADIOACTIVE TRACERS; SWINE; THROMBOSIS;

EID: 0038185142     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200304000-00003     Document Type: Article

References (32)

1. Muller C, Buttner HJ, Petersen J, Roskamm H, A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101:590-593.
2. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III- independent inhibitors. J Clin Invest 1990; 86:385-391.
3. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A 1989; 86:3619-3623.
4. Loscalzo J, Melnick B, Handin RI. The interaction of platelet factor four and glycosaminoglycans. Arch Biochem Biophys 1985; 240:446-455.
5. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol 2000; 12 (Suppl E):E14-18; discussion E25-28.
6. Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CL. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999; 84:1391-1395.
7. Chen WH, Lau CP, Lau YK, Ng W, Lee PY, Yu CM, Ma E. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002; 14:439-442.
8. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989; 79:657-665.
9. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits [see comments]. Circulation 1991; 84:232-243.
10. Buchwald AB, Sandrock D, Unterberg C, Ebbecke M, Nebendahl K, Luders S, et al. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol 1993; 21:249-254.
11. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333:764-769.
12. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995; 333:757-763.
13. Gladwell TD. Bivalirudin: a direct thrombin inhibitor. Clin Ther 2002; 24:38-58.
14. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002; 359:294-302.
15. Gallo R, Padurean A, Toschi V, Bichler J, Fallon JT, Chesebro JH, et al. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation 1998; 97:581-588.
16. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78:1286-1292.
17. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79:110-118.
18. Mehta JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, Saldeen TG. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 1998; 31:345-351.
19. Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 1997; 78:1404-1407.
20. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmstrom M, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999; 81:358-363.
21. Larsson MLU, Ahnhoff M, Lindmark B, Abrahamsson P, Svennberg H, Persson B-A. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B 2002; 766:47-55.
22. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin [see comments]. N Engl J Med 1992; 327:141-145.
23. The TRIM Study Group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double- blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. Eur Heart J 1997; 18:1416-1425.
24. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris [see comments]. J Am Coll Cardiol 1993; 21:1039-1047.
25. Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis [see comments]. Circulation 1998; 97:26-33.
26. McNamara CA, Sarembock IJ, Gimple LW, Fenton JWD, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor [see comments]. J Clin Invest 1993; 91:94-98.
27. Abendschein DR, Recchia D, Meng YY, Oltrona L, Wickline SA, Eisenberg PR. Inhibition of thrombin attenuates stenosis after arterial injury in minipigs [see comments]. J Am Coll Cardiol 1996; 28:1849-1855.
28. Buchwald AB, Hammerschmidt S, Stevens J, Goring J, Nebendahl K, Unterberg C. Inhibition of neointimal proliferation after coronary angioplasty by low-molecular-weight heparin (clivarine) and polyethyleneglycolhirudin. J Cardiovasc Pharmacol 1996; 28:481-487.
29. Sarembock IJ, Gertz SD, Thome LM, McCoy KW, Ragosta M, Powers ER, et al. Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. J Vasc Res 1996; 33:308-314.
30. Thome LM, Gimple LW, Bachhuber BG, McNamara CA, Ragosta M, Gertz SD, et al. Early plus delayed hirudin reduces restenosis in the atherosclerotic rabbit more than early administration alone: potential implications for dosing of antithrombin agents. Circulation 1998; 98:2301-2306.
31. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993; 71:778-782.
32. Walenga JM, Hoppensteadt D, Koza M, Pifarre R, Fareed J. Comparative studies on various assays for the laboratory evaluation of r-hirudin. Semin Thromb Hemost 1991; 17:103-112.